Cover Image

Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty

Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with high affinity for dopamineD2 and D1 receptors and the serotonin transporter. It is unusual in that it controlsserotonin, dopamine, and glutamate neurotransmission concurrently, all of which havebeen impl...

Full description

Saved in:
Bibliographic Details
Main Author: Mohamed, Wael Mohamed Yousef
Format: Article
Language:English
Published: 2022
Subjects:
R Medicine (General)
Online Access:http://irep.iium.edu.my/96215/9/96215_Atypical%20antipsychotic%20Lumateperone.pdf
http://irep.iium.edu.my/96215/
https://osf.io/preprints/africarxiv/26xec/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.iium.irep.96215
record_format dspace
spelling my.iium.irep.962152022-01-26T04:26:52Z http://irep.iium.edu.my/96215/ Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty Mohamed, Wael Mohamed Yousef R Medicine (General) Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with high affinity for dopamineD2 and D1 receptors and the serotonin transporter. It is unusual in that it controlsserotonin, dopamine, and glutamate neurotransmission concurrently, all of which havebeen implicated in severe mental illness. Consider it a multi-targeted ligand andmultifunctional modulator of the serotoninergic system with possible precognitive,antipsychotic, antidepressant, and anxiolytic properties. While lumateperone has beenexplored as a new agent for schizophrenia therapy, it also provides a unique therapeuticoption for a range of other psychiatric and neurological diseases, including behaviouralsigns of dementia or Alzheimer's disease, sleep problems, and bipolar depression.Additionally, it had a better safety profile than placebo, with no significant extrapyramidalside effects, hyperprolactinemia, or changes in cardiometabolic or endocrinecharacteristics. Additional study is needed to validate and analyse lumateperone's1 effectiveness, as well as to identify prospective therapeutic targets. This article gives acomprehensive overview of the most notable results and potential future applications ofthis chemical in personalised medicine, particularly for neurodegenerative diseases 2022-01-11 Article PeerReviewed application/pdf en http://irep.iium.edu.my/96215/9/96215_Atypical%20antipsychotic%20Lumateperone.pdf Mohamed, Wael Mohamed Yousef (2022) Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty. AfricarXiv. (In Press) https://osf.io/preprints/africarxiv/26xec/ 10.31730/osf.io/26xec
institution Universiti Islam Antarabangsa Malaysia
building IIUM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider International Islamic University Malaysia
content_source IIUM Repository (IREP)
url_provider http://irep.iium.edu.my/
language English
topic R Medicine (General)
spellingShingle R Medicine (General)
Mohamed, Wael Mohamed Yousef
Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty
description Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with high affinity for dopamineD2 and D1 receptors and the serotonin transporter. It is unusual in that it controlsserotonin, dopamine, and glutamate neurotransmission concurrently, all of which havebeen implicated in severe mental illness. Consider it a multi-targeted ligand andmultifunctional modulator of the serotoninergic system with possible precognitive,antipsychotic, antidepressant, and anxiolytic properties. While lumateperone has beenexplored as a new agent for schizophrenia therapy, it also provides a unique therapeuticoption for a range of other psychiatric and neurological diseases, including behaviouralsigns of dementia or Alzheimer's disease, sleep problems, and bipolar depression.Additionally, it had a better safety profile than placebo, with no significant extrapyramidalside effects, hyperprolactinemia, or changes in cardiometabolic or endocrinecharacteristics. Additional study is needed to validate and analyse lumateperone's1 effectiveness, as well as to identify prospective therapeutic targets. This article gives acomprehensive overview of the most notable results and potential future applications ofthis chemical in personalised medicine, particularly for neurodegenerative diseases
format Article
author Mohamed, Wael Mohamed Yousef
author_facet Mohamed, Wael Mohamed Yousef
author_sort Mohamed, Wael Mohamed Yousef
title Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty
title_short Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty
title_full Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty
title_fullStr Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty
title_full_unstemmed Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty
title_sort atypical antipsychotic lumateperone beyond schizophrenia: seeking clarity in a time of uncertainty
publishDate 2022
url http://irep.iium.edu.my/96215/9/96215_Atypical%20antipsychotic%20Lumateperone.pdf
http://irep.iium.edu.my/96215/
https://osf.io/preprints/africarxiv/26xec/
_version_ 1724072829018701824
score 13.211869

Similar Items